Drugs / EVUNZEKIBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04144842 | Dec 2019 → Mar 2023 | neoplasm | Alligator Bioscience AB | Completed | Met primary |
News releases announcing trial results or a regulatory action · 19
| Date | Issuer | Release |
|---|---|---|
| 2025-01-29 | Alligator Bioscience AB | Results Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer alligatorbioscience.se ↗
This publication validates ATOR-1017’s safety and tolerability in patients with advanced cancers and highlights early signs of clinical efficacy. |
| 2023-10-05 | Alligator Bioscience AB | Results Alligator Bioscience Announces Publication Highlighting ATOR-1017 Preclinical Data in the Scientific Journal “Cancer Immunology, Immunotherapy” alligatorbioscience.se ↗
Preclinical data demonstrate ATOR-1017's strong safety profile and potent therapeutic anti-tumor effect in vivo both as monotherapy and in combination with anti-PD-1 treatment |
| 2022-11-10 | Alligator Bioscience AB | Results Data presented on mitazalimab and ATOR-1017 in Two Poster Presentations at SITC Annual Meeting 2022 – November 8-12, 2022 alligatorbioscience.se ↗
New ATOR-1017 data show the 4-1BB monoclonal antibody is safe and well tolerated at doses up to 900 mg and demonstrates an excellent clinical profile as a potential best-in-class asset |
| 2022-11-01 | Alligator Bioscience AB | Results Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences alligatorbioscience.se ↗
Ana Carneiro, Associate Professor and Consultant at Lund University, will give a poster presentation entitled "ATOR-1017, a 4-1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies", poster number 714, on November 11. |
| 2022-09-30 | Alligator Bioscience AB | Results Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies alligatorbioscience.se ↗
The data show that for doses up to 900 mg there were no significant safety concerns with durable stable disease as the best tumor response, confirming previously announced signs of clinical benefit. |
| 2022-05-31 | Alligator Bioscience AB | Results Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022 alligatorbioscience.se ↗
The results, to be presented at ASCO, demonstrate an excellent safety profile. |
| 2022-04-01 | Alligator Bioscience AB | Results Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences alligatorbioscience.se ↗
The data indicate that for doses up to 600 mg, there were no significant safety concerns with stable disease as the best tumor response. |
| 2021-12-16 | Alligator Bioscience AB | Results Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data alligatorbioscience.se ↗
The early readout data corroborates previous data on biomarkers, safety and tolerability, sustaining a safety profile up to and including a dose of 360 mg with no dose limiting toxicities reported. |
| 2021-11-12 | Alligator Bioscience AB | Results Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021 alligatorbioscience.se ↗
Alligator Bioscience AB (“Alligator” or the “Company”) today announced new preclinical data highlighting the 4-1BB (CD137) antibody ATOR-1017 including an update on the ongoing phase 1 study. |
| 2021-06-04 | Alligator Bioscience AB | Results Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017 alligatorbioscience.se ↗
Safety data show that ATOR-1017 is safe and well tolerable at doses up to 200 mg and no dose limiting toxicity has occurred. |
| 2020-10-27 | Alligator Bioscience AB | Results Predicted therapeutic range dose levels reached in ATOR-1017 Phase I alligatorbioscience.se ↗
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety data from its ongoing clinical Phase I study of the drug candidate ATOR-1017, its wholly owned 4-1BB antibody in development for the treatment of metastasized cancer. |
| 2020-08-27 | Alligator Bioscience AB | Results Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study alligatorbioscience.se ↗
The data presented today displays an encouraging safety profile of ATOR-1017. |
| 2020-06-23 | Alligator Bioscience AB | Regulatory Alligator Bioscience receives first patent approval for ATOR-1017 alligatorbioscience.se ↗
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 10,689,454 which covers compositions of matter directed to Alligator’s drug candidate ATOR-1017, its wholly owned 4-1BB antibody in clinical Phase I development for the treatment of metastasized cancer. |
| 2019-11-06 | Alligator Bioscience AB | Results Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting alligatorbioscience.se ↗
Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinical data showing that their drug candidate ATOR-1017 can induce a long-lasting immunological memory which is of great importance in a potential future patient setting. |
| 2019-06-18 | Alligator Bioscience AB | Regulatory Alligator Bioscience submits clinical trial application for ATOR-1017 alligatorbioscience.se ↗
Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announced that the company has submitted clinical trial authorization (CTA) application to initiate a Phase I study of its fully owned 4-1BB antibody ATOR-1017 for the treatment of metastasizing cancer. |
| 2019-03-18 | Alligator Bioscience AB | Results Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017 alligatorbioscience.se ↗
The new data show that ATOR-1017, in an experimental model for colon cancer (MC38), displays potent anti-tumor effects. |
| 2018-09-28 | Alligator Bioscience AB | Results New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017 alligatorbioscience.se ↗
The new data include preclinical safety studies supporting a good tolerability profile of ATOR-1017. |
| 2018-06-21 | Alligator Bioscience AB | Results Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells alligatorbioscience.se ↗
These new data show that ATOR-1017 activates NK cells as well as T cells, both contributing to an effective immune-mediated killing of tumor cells. |
| 2018-05-03 | Alligator Bioscience AB | Results Alligator Bioscience: ATOR-1017 pre-clinical data support a best-in-class 4-1BB antibody profile alligatorbioscience.se ↗
The data support a best-in-class profile for ATOR-1017, with a strong potential for high efficacy and tumor-directed immune activation. |
All press releases naming this drug 23 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVUNZEKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095308 ↗ |
| Known as | ATOR-1017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04144842 ↗ |
| Modality | Monoclonal antibody | “ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)” NCT04144842 ↗ |
| Route | Intravenous | “administered by intravenous infusions” NCT04144842 ↗ |